Back to Results
First PageMeta Content
Health / Genentech / Macular degeneration / Ranibizumab / Novartis / Hoffmann-La Roche / Off-label use / Presumed ocular histoplasmosis syndrome / Medicine / Pharmacology / Bevacizumab


Avastin vs Lucentis Letter sent to Vice-President Almunia on November 7th, 2013 Contact: Ilaria Passarani – [removed] Ref.: BEUC-X[removed]/2014
Add to Reading List

Document Date: 2014-03-05 04:20:37

Open Document

File Size: 252,85 KB

Share Result on Facebook

City

Brussels / /

Company

Roche Holding AG / Novartis / AMD / Lucentis Dear / Roche / Genentech / /

Country

United States / /

Currency

USD / EUR / /

/

Event

M&A / Business Partnership / /

/

IndustryTerm

cancer treatment / health care systems / pharmaceutical products / /

Organization

Italian Antitrust Authority / European Medicines Agency / European Consumer Organisation / European Commission / European Union / /

Person

Ilaria Passarani / Almunia / /

/

Position

Vice-President / Monique Goyens Director General / /

Product

Avastin / Lucentis / /

ProgrammingLanguage

EC / /

URL

http /

SocialTag